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Abstract
Background: Phenethylisothiocyanate (PEITC) is produced by Brassica food plants. PEO is a PEITC Essential Oil 
containing >95% natural PEITC. PEITC is known to produce various health benefits but its effect in alleviation of 
ulcerative colitis signs is unknown.
Results: In two efficacy studies (acute and chronic) oral administration of PEO was effective at remitting acute and 
chronic signs of ulcerative colitis (UC) in mice. Disease activity, histology and biochemical characteristics were 
measured in the treated animals and were compared with appropriate controls. PEO treatment significantly improved 
body weights and stool consistency as well as decreased intestinal bleeding. PEO treatment also reduced mucosal 
inflammation, depletion of goblet cells and infiltration of inflammatory cells. Attenuation of proinflammatory 
interleukin1β production was observed in the colons of PEO-treated animals. Expression analyses were also carried out 
for immune function related genes, transcription factors and cytokines in lipopolysaccharide-activated mouse 
macrophage cells. PEO likely affects an intricate network of immune signaling genes including a novel concentration 
dependent reduction of total cellular Signal Transducer and Activator of Transcription 1 (STAT1) as well as nuclear 
phosphorylated-STAT1 (activated form of STAT1). A PEO-concentration dependent decrease of mRNA of C-X-C motif 
ligand 10 (a STAT1 responsive chemokine) and Interleukin 6 were also observed.
Conclusions: PEO might be a promising candidate to develop as a treatment for ulcerative colitis patients. The disease 
attenuation by PEO is likely associated with suppression of activation of STAT1 transcription and inhibition of pro-
inflammatory cytokines.
Background
Inflammatory bowel disease (IBD), affecting an estimated
two million people annually in the US [1,2], is predomi-
nantly comprised of Crohn's disease (CD) and ulcerative
colitis (UC). IBD is a set of chronic and relapsing inflam-
matory disorders of the intestine caused by multifactorial
conditions in a genetically predisposed individual. UC
primarily affects the mucosal lining of the colon and rec-
tum, whereas CD may extend to any part of the gastroin-
testinal tract and is characterized by transmural
inflammation [2,3]. Since the etiology of both CD and UC
remains unclear, successful treatment strategies targeting
wider sections of the population have not been found. In
recent years meta-analyses of clinical trials have been
performed in several instances to establish efficacy of
antibiotic and other therapies. Non-steroidal anti-inflam-
matory drugs such as Asacol, and immune-suppressive
agents are commonly used to treat IBD alone or in com-
bination with short-term antibiotic therapies [4-6]. While
adjunct antibiotic therapies may be useful [6], their long
term use is not common for reasons beyond the scope of
discussion here. Other oral therapies generally for long
term remission and to prevent flare-up, to which not all
patients adequately respond, are often combined with
surgical interventions of the colon. Patients with pro-
longed UC are at an increased risk for developing colitis-
associated cancer (CAC) [7]. Long-term use of some IBD
therapies can reduce the risk of CAC by 75-81% in
responding patients [8]. Side effects of existing treat-
ments, such as kidney damage from long-term use of
mesalamine (Asacol) or increased risk of infections from
use of immune suppressive agents are common [4,5]. The
lack of efficacious drugs to treat the general patient popu-
lation, combined with the prevalence of negative side
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effects, emphasizes the need for the development of new,
effective, and well-tolerated anti-inflammatory therapies
for UC. Alternative treatments, including botanical ther-
apies, have been proposed [9]. Unfortunately, objective
e v i d e n c e  o f  c o n s i s t e n t  e f f i c a c y  a n d  s a f e t y  o f  b o t a n i c a l
products is generally nonexistent, despite their gain in
public acceptance [9].
A combination of genetic susceptibility factors and an
altered immune response driven by enteric microbial fac-
tors and oxidative stress, contributes to the initiation and
chronification of IBD as suggested by various animal
models [10,11]. Chemically induced intestinal inflamma-
tion is among the most commonly used IBD animal mod-
els, as the onset of inflammation is immediate and the
procedure is relatively straightforward. Among the chem-
ical models, the dextran sodium sulfate- (DSS) induced
model of bowel inflammation can be adapted for the
study of both acute and chronic colitis and can be
extended for the study of CAC [11]. In addition, the DSS-
induced model recreates some important immunological
and histopathological aspects of IBD occurring in
humans.
Isothiocyanates (ITCs) are naturally occurring sulfur-
containing compounds commonly found in Brassicaceae
family vegetables such as cabbage, cauliflower, watercress
and broccoli [12]. Phenethylisothiocyanate (PEITC) is a
well-studied ITC, occurring naturally in the form of its
glucosinolate precursor, gluconasturtiin. Barbarea verna
is a Brassicaceous herb that is used in salads, soups, and
garnishes and in our study is one of the richest sources of
dietary PEITC, with the highest levels contained in the
seeds [13]. PEITC showed chemopreventive activity
against various cancers [13,14] and no apparent toxicity
even when administered in high doses in rats and dogs as
determined by NOEL (no-observed-adverse-effect-level)
in drug safety studies [15]. It is also known for other ben-
eficial effects such as anti-oxidative and anti-inflamma-
tory activities [16-19]. PEITC inhibited Nuclear Factor
kappaB (NFκB) activity in colon cancer cells and mac-
rophages [16-18,20]. Our previous study [19] showed that
PEITC was the most effective of several ITCs tested in
suppressing expression of NFκB-regulated proinflamma-
tory genes. In the same study PEO (PEITC essential oil,
>95% natural PEITC from B. verna) had strong anti-
inflammatory activity, reducing paw edema in rats with
an effect that was comparable to that of the reference
drug aspirin administered at the same concentration [19].
Research shows that PEITC is stable in biological samples
and has high oral bioavailability in rats [21]. Here, we
report the efficacy of PEO in alleviating clinical signs of
DSS-induced acute and chronic colitis in mice. Using in
vivo and in vitro models, we have measured effects of
PEO on disease activity index, histological parameters,
and changes in proinflammatory cytokine levels as well as
changes in expression and activation of a key transcrip-
tion factor, Signal Transducer and Activator of Transcrip-
tion (STAT1). To the best of our knowledge no prior
report has evaluated the anti-inflammatory effects of
PEITC on IBD in mammalian models.
Methods
Chemicals and Biochemicals
Antibiotics, dimethyl sulphoxide (DMSO), LPS (lipo-
polysaccharide from E.coli, serotype 055:B5) and PEITC
standard were purchased from Sigma Chemicals (St.
Louis, MO), 5-amino salicylic acid (5-ASA, also known as
mesalamine) from TCI America (Portland, OR) and DSS
from MP Biomedicals (Solon, OH). All other chemicals,
including cell culture media, were obtained from Invitro-
g e n Inc.  ( Car ls ba d,  CA).  R ea g e n ts  used in qua n t ita t ive
P C R ,  i n c l u d i n g  e n z y m e s ,  w e r e  s u p p l i e d  b y  S t r a t a g e n e
Inc. (La Jolla, CA), cress seeds (certified non-contami-
nated) from Kitazawa Seed Company (Oakland, CA) and
RAW 264.7 cell line (ATCC TIB-71) from American Type
Culture Collection (Manassas, VA). All antibodies were
obtained from Santa Cruz Biotechnology Inc (Santa
Cruz, CA), unless otherwise mentioned.
Preparation of PEO
PEO (containing >95% PEITC) was extracted by hydro
distillation of ground winter cress seed as was previously
described in Ribnicky et al., [13] and Dey et al., [19]. Gas
chromatography/mass spectroscopy (GC/MS) was used
to confirm the purity of the obtained PEO. The samples
were injected into a Hewlett-Packard mass spectrometer
(model 5890/5971) equipped with a 30-m × 0.25 mm DB-
5 MS fused silica capillary column (J&W Scientific, Fol-
som CA). Chromatographic parameters were as previ-
ously described [13,19]. The retention time of PEITC is
11.3 min. The major ion of PEITC has a mass of 91 (m/z)
and molecular ion of mass 163 (m/z). The abundance of
these ions and the integration value of the entire peak
were used together with standard curves created previ-
ously from a PEITC chemical standard (Sigma Chemi-
cals, St. Louis, MO) to quantify the PEITC in PEO.
In vivo animal studies
All studies were performed in accordance with the Guide
for the Care and Use of Laboratory Animals as adopted
and promulgated by the U.S. National Institutes of
Health. C57BL/6J male mice, seven weeks old, were used.
The mice were housed in a room maintained at a con-
stant temperature of 24-26°C with 12-h light/dark cycle
and had free access to food (Purina chow) and drinking
water. Before the start of experiments, one week was
allowed for their acclimatization to these conditions. Two
m u r i n e  m o d e l s  o f  c o l i t i s ,  t h e  c h r o n i c  a n d  a c u t e ,  w e r e
used following Aharoni et al., [5] and Wirtz et al., [11].Dey et al. BMC Chemical Biology 2010, 10:4
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The mice were randomized into four groups, which are
described in Table 1. For the acute and chronic models,
each of the groups, except healthy controls, consisted of 6
and 10 animals respectively, housed 3-4 per cage. The
healthy control (water group) consisted of 4 animals in
both experiments. Development (and variation) of clini-
cal signs was not anticipated in this group, hence the
small number was determined to be sufficient. Treating
this group with vehicle helped to account for any stress
among animals due to daily oral gavage.
1. Acute model of colitis: Acute ulcerative colitis was
induced by freshly prepared 3% DSS (ad libitum) in
drinking water for five days (Table 1). In a separate exper-
iment we had previously tested various DSS concentra-
tions (2-4%) for acute disease development (data not
shown). At a concentration higher than 3% DSS, some
deaths occurred that corresponded with severity of clini-
cal signs. Therefore, we used the highest tolerated con-
centration of 3% for our actual experiment. Mice were
observed individually once a day for their general health
conditions, including body weight, diarrhea, rectal bleed-
ing and inflammation and rectal prolapse. Occult bleed-
ing was tested daily in stool per cage using a commercial
ColoScreen Kit (Helena Laboratories, Beaumont, TX).
Disease activity index (DAI) (Fig 1) was determined fol-
lowing the scheme shown in Table 2. On the 15th day
post-treatment, mice were sacrificed using carbon diox-
ide inhalation. Colons were collected terminally, mea-
sured for their gross length, and flushed with sterile
phosphate-buffered saline without calcium and magne-
sium (Gibco Carlsbad, CA) containing 20 μg/ml gentam-
ycin (Sigma Chemicals, St Louis, MO). Entire colons were
then stored in histology cassettes immersed in 10% neu-
tral buffered formalin. Paraffin cross-sections (6 μm)
were stained with hematoxylin and eosin (H&E) for histo-
logical evaluation (×200 magnification) of colonic dam-
age. Histopathological assessment was performed in a
blinded manner following the published scoring system
[11] (Table 3, Fig 2).
2. Chronic model of colitis: Chronic colitis was induced
by four cycles of 9 days of alternating DSS and tap water
(ad libitum) (detailed in Table 1). Each 9-day cycle con-
sisted of 3 days of 2.5% DSS, followed by 6 days of tap
water. Treatment regimens and sacrifice of mice were the
same as in acute model except that necropsy was carried
out on day 16. Five samples from each group, except
water group, were collected for histopathology as
described for the acute model, and remaining five were
collected for full thickness organ culture as described by
Wirtz et al., [11]. Similarly for the control water group,
two were collected for full thickness organ culture and
two for histopathology. All clinical assessments were per-
formed as described for acute model above.
Organ culture and ELISA
Two biopsy punches were terminally collected from each
of the proximal middle and distal parts of individual
colons using a 3 mm dermal punch biopsy instrument
(Miltex, York, PA). Each biopsy specimen was transferred
into separate wells of a 48-well microtiter plate contain-
ing 500 μl of supplemented RPMI1640 media (Gibco,
Carlsbad, CA) and incubated at 37°C for 12 hours in a cell
culture incubator [11]. Supernatants were collected and
stored at -20°C until further use. Interleukin1β (IL1β)
protein levels released by the biopsy samples in the media
were assessed with a quantitative enzyme-linked immu-
nosorbent assay kit (ELISA) (Bender Med Systems, Burl-
ingame, CA), according to manufacturer's instruction,
and the values were expressed as pg/ml (Fig 3).
Macrophage Cell Culture Assay
The mouse monocyte/macrophage cells, RAW 264.7
(ATCC TIB-71), were cultured and treated as previously
described by Dey et al., [19].
Cell Viability Assay and Dose Range Determination
A Cell Titer 96 MTS assay kit (Promega Corp., Madison,
WI) was used to determine the relative number of viable
Table 1: In vivo experimental set-up for acute and chronic colitis models
Groups Acute model
(5 days induction, ad libitum)
Chronic model
(36 days induction, ad libitum)
Treatment
(14 days, once daily)
Comment
Water Tap water Tap water Vehicle (9% 
DMSO+corn oil)
Healthy control
DSS 3% DSS 2.5% DSS (3 days) followed by 
tap water (6 days), 4 cycles
Vehicle (9% 
DMSO+corn oil)
Diseased 
control*
PEO 3% DSS 2.5% DSS (3 days) followed by 
tap water (6 days), 4 cycles
PEO 75 mg/kg (>95% 
PEITC)
Unknown test 
group
5-ASA 3% DSS 2.5% DSS (3 days) followed by 
tap water (6 days), 4 cycles
5-ASA 50 mg/kg Reference test 
group
* Statistical significance of treatments of PEO and 5-ASA groups are shown with respect to DSS group, unless otherwise mentionedDey et al. BMC Chemical Biology 2010, 10:4
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cells remaining after incubation with treatments. For
actual in vitro experiments with PEO, the highest non-
toxic concentration or less was selected.
Total RNA Extraction, Purification, and cDNA Synthesis
Total RNA extraction, purification and cDNA synthesis
were performed as described previously in Dey et al.,
[19].
Real Time Quantitative PCR and Gene Array
Q-RT-PCR was performed as previously described [19].
Gene-specific primers (IDT Inc., Coralville, IA) used in
the current study are described in Table 4. For gene array
experiments (Table 5), PCR-arrays (APM_025, SABiosci-
ences Inc, MD) were purchased and manufacturer's pro-
tocol was followed. Relative quantification using SYBR
green technology and standard ΔΔCt method was used
for individual RT-PCR and gene array experiments. Data
are expressed as relative mRNA quantity with respect to
LPS-elicited control (positive control) which is normal-
ized to a value of 1.0 as described in Dey et al., 2006 [19]
(Fig 4).
Immuno-blotting
For immunoblot analyses, pretreated RAW 264.7 cells
were activated with LPS for 45 minutes and harvested
using RIPA lysis buffer (Pierce biotechnology, Rockford,
IL). For nuclear extract preparation and protein concen-
tration determination manufacturer's (Thermo Scientific,
Rockford, IL) protocols in NE-PER Nuclear Extraction
Reagents and Pierce BCA Protein Assay kit were fol-
lowed. Proteins (50 μg/lane) were separated by 12% SDS-
PAGE and products were electrotransferred to polyvi-
nyldene difluoride (PVDF) membranes (Amersham Bio-
sciences Corp, Piscataway, NJ). The membranes were
blocked with 5% skim milk for 1 h, washed 3 times in
PBS, incubated with primary Ab (Abs against mouse
βactin and STAT1 were purchased from Santa Cruz Bio-
technology Inc., Santa Cruz, CA and against phosphory-
lated [Tyr701] STAT1 from Cell Signaling Technology Inc,
Beverly, MA) for 1 h, washed 3 times in PBST (PBS con-
taining 05% Tween20) and incubated with HRP-conju-
gated secondary Ab (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) for 1 h, all at room temperature. After an
additional 3 washing steps, bound peroxidase activity was
detected by ECL detection system (Amersham Biosci-
ences Corp, Piscataway, NJ) (Fig 5).
Statistical Analysis
Data are expressed as mean ± SE. Analyses for in vitro
experiments were performed using Student's t-test. One-
way ANOVA (analysis of variance) was used to determine
the significance of in vivo treatments followed by post-
ANOVA Tukey's Honestly Significant Difference multiple
means comparison test to determine specificity of the
treatments.
Results
For convenient interpretation of the data discussed in the
subsequent sections, the current paragraph highlights
key features of the method section. The acute model is
Table 2: Disease Activity Index (DAI) to assess clinical colitis in mice (modified based on Aharoni et al., 2006; Wirtz et al., 
2007)
Score Body wt change (%) Internal 
intestinal 
bleeding, FOBT 
test strip 
(colorimetric)
Rear end visible 
bleeding+ 
inflammation
Stool 
consistency
*Rectal prolapse
0 Gain, loss <1 No color change Negative Normal None
1 Loss 1-5 - Either one, mild - -
2 Loss 5-10 Color change Either one, severe Loose Observed
3L o s s  1 0 - 1 5 - B o t h ,  m i l d -
4 Loss >15 - Both, severe Diarrhea -
* Rectal prolapse was only observed in the chronic model
Table 3: Scoring system for inflammation-associated 
histological changes in the colon (Wirtz et al., 2007)
Score Histologic changes
0 No evidence of inflammation
1 Low level of inflammation with scattered 
infiltrating mononuclear cells (1--2 foci)
2 Moderate inflammation with multiple foci
3 High level of inflammation with increased 
vascular density and marked wall thickening
4 Maximal severity of inflammation with 
transmural leukocyte infiltration and loss of 
goblet cellsDey et al. BMC Chemical Biology 2010, 10:4
http://www.biomedcentral.com/1472-6769/10/4
Page 5 of 12
defined by rapid onset of severe clinical signs (sometimes
interchangeably referred to as 'symptoms' in the rest of
the text) that may be healed when the disease-causing
agent (DSS) is withdrawn. The induction period in the
acute model is shorter than in the chronic model and a
higher DSS concentration is used. In the chronic model,
induction of symptoms is slower but longer lasting with
possible flare-up and remission cycles. DSS is adminis-
tered in alternate cycles at lower concentrations for the
chronic model (see Table 1 and methods). The optimal
concentration of PEO (75 mg/kg) for assessing its in vivo
efficacy was determined in a pilot study using a dose
response administration of PEO in DSS-treated animals
(data not shown). Mesalamine/5-ASA, a standard first-
line therapy for mild-to-moderate UC, administered at a
recommended 50 mg/kg [22], was used as a reference
standard for in vivo models. In all instances, statistical
significances of treatments of PEO and 5-ASA groups
were compared to DSS group (Figs 1, 2, 3, Table 1). The
results are presented in the order of physiological, histo-
pathological and molecular observations. In the sections
to follow, the 'water-group' and the 'DSS-group' refer to
the healthy and the disease controls respectively (see
Table 1 for details).
Disease activity index (DAI) (Fig 1) combined the fol-
lowing 5 variables (clinical signs/symptoms): change in
body weight, stool consistency, occult blood in stool, rear
end bleeding and inflammation (visible), and rectal pro-
trusion. DAI was used to compare the treatment response
to PEO and 5-ASA with that of the DSS group following
the scale described in Table 2 [modified from [5,11]].
Rectal prolapse, one of the variables for DAI (Table 2) was
observed only in the chronic colitis animals (Fig 1B)
occurring with partial prolapse of the rectal lining.
Therefore, the DAI shown for the acute model (Fig 1A)
does not reflect this variable. Also, UC is an intermittent
disease with periods of exacerbated symptoms and peri-
ods that are relatively symptoms free [11,23]. Due to the
Table 4: Primer sequences used for real-time RT-PCR
Gene (accession number) Forward Reverse
IL6 (NM_031168) 5'-tagtccttcctaccccaatttcc-3' 5'-ttggtccttagccactccttc-3'
CXCL10/IP10 (NM_021274) 5'attctttaagggctggtctga 3' 5'cacctccacatagcttacagt 3'
β Actin (NM_007393) 5'-aaccgtgaaaagatgacccagat-3' 5'-cacagcctggatggctacgt-3'
IL6, Interleukin6; CXCL10/IP10, C-X-C motif ligand 10/10 kDa interferon-gamma-induced protein
Figure 1 Effects of orally administered PEO and 5-ASA on the Disease activity index (DAI) in DSS-induced colitis. Experimental mouse groups 
and disease induction are defined in Table 1 and scoring criteria in Table 2. Significance of treatments in PEO and 5-ASA groups in respect to DSS 
group and are indicated by *, p < 0.05 and **p < 0.01 and ***p < 0.001. (A) Acute colitis model. Data as mean ± SEM (n = 6) are shown at five-day 
intervals. (B) Chronic colitis model. Data as mean ± SEM (n = 10) are shown at three-and two-day intervals during induction and treatment periods 
respectively.
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longer experimental duration of the chronic model (Table
1), the relapse-remission pattern among members of indi-
vidual groups was observed (Fig 1B). In the acute model,
both PEO and 5-ASA attenuated the general signs of UC
after 5, 10 and 15 days of respective treatments (Fig 1A)
with PEO performing notably better (PEO p < 0.01, 5-
ASA  p  < 0.05) and comparing closely with the water
(healthy) group (Fig 1A). In the chronic model, alleviation
of clinical signs was not observed until after 10 days of
treatment (Fig 1B). The PEO-treated group showed sig-
nificant amelioration (p < 0.01) of symptoms on day 12
and continued to experience further relief until the end of
the experiment while the 5-ASA group did not show any
significant remission (Fig 1B). In addition, the PEO-
treated group experienced an attenuated spike in symp-
toms starting from the second day of treatment (p < 0.01),
suggesting that PEO may also prevent the relapsing
nature of chronic colitis (Fig 1B).
Colon characteristics were analyzed next. Colon
lengths were measured prior to flushing. The healthy
water group typically had longer, non-thickened colons.
Figure 2 Effects of orally administered PEO and 5-ASA on colon length and histopathology. Experimental groups (chronic) and disease induc-
tion are defined in Table 1. (A) The DSS receiving groups had shorter average colon length as compared to water group (healthy controls) (n = 10). 
The shortening was relieved significantly in PEO treated group with respect to DSS group (*, p < 0.05). (B) Histogram showing blinded histo-patholog-
ical scores (n = 5; #, p = 0.07; +, p = 0.08) (C) Representative section (×200) from healthy (water) control group showing intact goblet cells and absence 
of inflammatory cells (D) Representative section (×200) from DSS group showing massive inflammatory cell aggregates and extensive loss of goblet 
cells (E) Representative section (×200) from PEO-treated group showing partial loss of goblet cells but absence of inflammatory cell accumulation (F) 
Representative section (×200) from 5-ASA-treated group showing minor loss of goblet cells and moderate infiltration of inflammatory cells. M, muco-
sa; SM, submucosa; ME, muscularis; Goblet cells are shown with yellow triangles with black borders; Inflammatory cells are marked with white triangles 
with red border. Histopathology was analyzed from H&E stained colon sections (6 μm).
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Table 5: Genes down-regulated (≥ 3-fold vs LPS activation alone) by 10 μM PEO in macrophages
Gene name
abbreviation
Gene name full Partial Gene Ontology term
 http://www.geneontology.org
Fold change in 
response to LPS
CCL2* Chemokine (C-C motif) ligand 2 Inflammatory response; Chemokine activity -35.67
CSF2 Colony stimulating factor 2 
(granulocyte- macrophage)
Immune response; Cytokine and chemokine 
mediated signaling pathway
-8.21
CSF3 Colony stimulating factor 3 
(granulocyte)
Immune response; Cytokine activity -53.69
CXCL10* Chemokine (C-X-C motif) ligand 10 Inflammatory response; Chemokine activity -30.05
FOS FBJ osteosarcoma oncogene DNA binding; Regulation of transcription -10.90
GJA1 Gap junction membrane channel 
protein alpha 1
Cell-cell signaling -19.25
IL10 Interleukin 10 Immune response; Cytokine activity -4.95
IL1a Interleukin 1 alpha Inflammatory response; Cytokine activity -291.36
IL1b Interleukin 1 beta Inflammatory response; Cytokine activity; 
Neutrophil chemotaxis; Positive regulation of IL-
6 and chemokine biosynthesis
-32.83
IL6* Interleukin 6 Signal transducer and cytokine activity -14.39
MAPK3 Mitogen activated protein kinase 3 ATP binding; Transferase activity; Protein amino 
acid phosphorylation; Signal transduction; 
Inflammatory response; Regulation of cytokine 
biosynthesis; MAP kinase activity
-3.11
NFkB1 Nuclear factor of kappa light chain 
gene enhancer in B-cells 1, p105
DNA binding; Regulation of transcription -21.51
NFkB2 Nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 2, p49/p100
DNA binding; Regulation of transcription -5.72
NFkBia Nuclear factor of kappa light chain 
gene enhancer in B-cells inhibitor, 
alpha
Nucleus; Protein binding; Cytoplasm: Regulation 
of cell proliferation; Protein-nucleus import, 
translocation
-8.21
REL Reticuloendotheliosis oncogene DNA binding; Regulation of transcription -5.76
RELb Avian reticuloendotheliosis viral 
(v-rel) oncogene related B
Transcription factor activity; Intracellular; T-
helper 1 type immune response
-3.78
RIPK2 Receptor (TNFRSF)-interacting 
serine-threonine kinase 2
Regulation of apoptosis -5.72
SLC20a1* Solute carrier family 20, member 1 Receptor activity; Phosphate transport -6.81
STAT1* Signal transducer and activator of 
transcription 1
DNA binding; Regulation of transcription -4.81
TNFaip3* Tumor necrosis factor, alpha-
induced protein 3
Apoptosis; Zinc ion binding -134.05
CD40* CD40 antigen Signal transduction; Immune response; 
Apoptosis
-46.74
* Novel hits (genes) suppressed by PEITC/PEO (previously not reported)
In the diseased animals, the colons were often shortened
(Fig 2A), likely due to loss in crypt structure and thick-
ened due to edema formation, similar to previously
reported studies with this model [24]. The differences
between the healthy and the DSS-receiving groups in
terms of colon lengths were less pronounced in the acute
study (data not shown) as compared with the chronic
study (Fig 2A), likely due to shorter induction period (5
days vs 36 days). Therefore, relief from colon shortening-
effects was not observed in the acute model. In the
chronic study, all of the DSS-treated groups (Table 1) had
markedly shorter average colon lengths as compared with
the healthy water-treated group (Fig 2A). The PEO-
treated group exhibited pronounced attenuation of colon
shortening (p < 0.05, Fig 2A) as was observed terminally.Dey et al. BMC Chemical Biology 2010, 10:4
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Histology of the bowel sections of the experimental ani-
mals revealed a number of cellular changes in the colons
as described in Table 3[11]. However, the population size
available for histopathology study (Fig 2B) was smaller (n
=  5 )  a s  c o m p a r e d  t o  t h e  o b s e r v a t i o n s  f o r  g r o s s  c o l o n
length (n = 10) (Fig 2A). This is because half of the 10
colons were used for biopsy samples (discussed later, Fig
3) and half were available for histopathological evalua-
tions. The PEO-treated group had the lowest average
pathological score (p = 0.07), closely followed by the 5-
ASA group (p = 0.08) (Fig 2B). Qualitative differences
were widespread among the bowels of both the PEO (Fig
2E) and 5-ASA (Fig 2F) groups relative to the DSS group
(Fig 2D). In the bowels of the DSS treated animals, mod-
erate to extensive infiltration of submucosa ('SM', Fig 2)
and superficial muscularis ('ME', Fig 2) by a mixed popu-
lation of inflammatory cells (shown in white triangles
with red border, Fig 2), such as lymphocytes, plasma cells,
and macrophages (all mononuclear type), was observed.
In some samples the infiltration extended transmurally
through the muscularis and into the serosa (data not
shown). The epithelium in small patches had frequently
lost the majority of their goblet cells (shown in yellow tri-
angles with black borders, Fig 2) or ulcerated away from
mucosa with intense infiltration of polymorphonuclear
neutrophylic leukocytes (PMNs) beneath ulcerated areas,
in contrast to the representative healthy colon section
(Fig 2C). Rectal parts of the colons were generally charac-
terized with the worst pathology including extensive infil-
tration, the presence of hyperplastic squamous
epithelium and an increased mitotic index (data not
shown). In the bowels of PEO- and 5-ASA-treated groups
(Figs 2E, F) some signs of ulceration, partially inflamed
submucosa, and low inflammatory cell infiltration were
also observed, but to a much lesser extent and infre-
quently, in contrast to the DSS group (Fig 2D). Addition-
ally, crypt structures with intact goblet cells were
frequently visible (Figs 2E, F).
In order to address the biochemical basis of histological
alterations, the cytokine response in the gut was evalu-
ated by measuring the release of the pro-inflammatory
cytokine, Interleukin 1β (IL1β) from colon tissue. A sig-
nificant reduction in the average production of IL1β in
the proximal (p < 0.01) and distal (p < 0.05) colon biopsies
was observed among PEO-treated animals as compared
with the DSS group. There was also a marked reduction
in cytokine production in the mid colon for the PEO
group (p = 0.06) (Fig 3). The average IL1β production was
reduced by 5-ASA in the middle and distal colons.
In the present study, histopathological analyses showed
infiltration by various inflammatory cells including mac-
rophages in the diseased samples and a reduction of such
infiltration in the PEO treated group. Subsequently, we
performed a gene array analysis (Table 5) using the same
in vitro macrophage based system to elucidate additional
immune signaling genes that could be potential targets of
PEO activity. Twenty one out of 84 genes (25%) induced
by LPS, were suppressed three-fold or more by 10 μM
Figure 4 Concentration dependent mRNA expression of IL6 and 
CXCL10 (selected novel hits presented in Table 5) in response to 
PEO treatments in LPS-activated mouse macrophage. Effect of 
PEO treatment was measured by the relative mRNA quantity of the 
genes of interest in the treated cells with respect to that of LPS activa-
tion only (positive control) that is normalized to a value of 1.00; β actin 
served as an internal control. Lower values represent greater inhibitory 
effects with 0.00 corresponding to a complete inhibition of the in-
duced gene expression; Values are mean ± S.E. **, p < 0.01; ***p < 
0.001. The gene expression was amplified using Real time RT-PCR.
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Figure 5 Immunoblot analyses showing suppression of total cel-
lular STAT1 (selected novel hit from Table 5) as well as activated 
nuclear pSTAT1 in response to PEO treatments in LPS-activated 
mouse macrophage. Cells were pre-treated with PEO for 2 h prior to 
45 min LPS-activation. Unstimulated cells and stimulated cells served 
as naïve and positive controls. Figure is representative of three experi-
ments. Significance of PEO treatment with respect to positive control 
is discussed in results section.
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PEO as compared to LPS activation alone (Table 5). LPS
is a known agonist of toll-like receptor 4 signaling that
plays a critical role in colitis [25]. Two genes that were
down-regulated by LPS and up-regulated by PEITC were
Htr2b (5-hydroxytryptamine, NM_008311) and Zap70
(zeta chain associated protein, NM_009539). LPS activa-
tion (or suppression) was separately compared to non
activated levels of gene expressions (data not shown). The
21 down regulated genes represent key transcription fac-
tors and inflammatory mediators, at least 7 of which
including IL6 were previously unknown to be affected by
PEITC/PEO treatment (Table 5). There is one very recent
report [26], however, showing in vitro down regulation of
some oncogenes by PEITC in response to IL6 elicitation
but effects of PEITC on IL6 expression was not reported.
Out of these 7 responding genes, concentration-depen-
dent changes in IL6, CXCL10 and STAT1 (signal trans-
ducer and activator of transcription1) expressions have
been confirmed using real time RT-PCR (Fig 4) and
Western Blot analyses respectively (Fig 5). These three
genes were selected for further examination since their
activation has been reported for human ulcerative colitis
[27-29]. At 10-15 μM, a decrease in mRNA and protein
levels was observed for all these three genes (p < 0.01)
(Figs 4, 5).
I L - 6  s i g n a l i n g  i s  m e d i a t e d  b y  S T A T 3  a n d  v a r i o u s
inflammatory diseases including UC are associated with
STAT3 activation [26]. But since activity of PEITC on
STAT3 activation is known [26], our subsequent investi-
gation focused on effects of PEO on STAT1 activation
and expression. Concentration dependent suppression of
cytoplasmic STAT1 protein (Fig 5) and mRNA (data not
shown) levels were observed. Additionally, CXCL10, a
STAT1 responsive gene [30] was also suppressed by PEO
in activated macrophages (Fig 4). We previously reported
suppression of another STAT1 responsive gene, iNOS by
PEO [19]. Therefore, we wanted to study the effects of
PEO on activated (phosphorylated at Tyr701) STAT1
(pSTAT1). Since within seconds after phosphorylation
STAT1 translocates into the nucleus for binding to the
DNA of its target genes [31], we determined the levels of
pSTAT1 in the nuclear fractions of the PEO treated cells.
A concentration dependent attenuation of pSTAT1 was
observed (Fig 5). Densitometric analysis revealed a 2.5-,
4-, and 5-fold (p < 0.05, with respect to LPS control)
reduction in pSTAT levels by one, 5 and 10 μM PEO. At
15 μM PEO treatment, pST A T was almost absent (p <
0.001) as was also observed in non-stimulated cells (Fig
5).
Discussion
Barbarea verna seeds are a rich source of PEITC with the
potential for providing natural protection from environ-
mental and dietary toxins [13]. We have previously
reported the anti-inflammatory properties of PEO [19].
PEO, an essential oil extracted from edible B. verna, con-
taining >95% naturally occurring PEITC, was used for all
experiments in the present study. Here, we present the
effects of PEO in mouse ulcerative colitis models. The
colitis was chemically induced with DSS and clinical signs
comparable to those of human ulcerative colitis [32] were
observed such as body weight loss, diarrhea, bloody stool,
mucosal ulceration, and shortening of colon length [33].
DSS is directly toxic to the gut epithelial cells by weaken-
ing the integrity of the mucosal barrier [11]. When given
at a higher concentration (3%) for a short duration (five
days), DSS induced acute colitis, while long-term (36
days) and cyclic (alternated with tap water) administra-
tion of a lower concentration (2.5%) of DSS developed
signs of chronic colitis [modification of [5,11]]. After dis-
ease induction, 75 mg/kg PEO was administered orally,
once daily for two weeks. The PEO treatments signifi-
cantly suppressed DSS-induced colitis in acute as well as
chronic models, improving their body weights and stool
consistency, as well as decreasing their intestinal bleeding
(combined together as DAI, Fig 1). In addition, PEO
reduced mucosal inflammation, depletion of goblet cells,
and infiltration of inflammatory cells, thereby preserving
colon length and structure (Fig 2). The observed attenua-
tion of histopathological signs of colitis (Fig 2) was not as
pronounced as the remission of the physiological symp-
t o m s  ( F i g  1 )  a f t e r  2  w e e k s  o f  P E O - t r e a t m e n t .  T h i s  i s,
however, consistent with the published report that com-
plete healing of bowel ulceration may not always occur in
parallel with clinical remission of symptoms [23]. Various
clinical studies also suggest that mucosal restitution is
usually measured after 8 weeks of treatments [23]. The
effects of the reference drug 5-ASA (also known as
mesalamine) administered at a dose of 50 mg/kg [22],
produced comparable DAI to that of PEO in the acute
model (Fig 1A) but were less pronounced in the chronic
model (Fig 1B). It is interesting to note that although
w i d e l y  u s e d  a s  a  f i r s t - l i n e  t h e r a p y  f o r  U C ,  5 - A S A  i s
largely ineffective in more severe and chronic cases of the
disorder [34]. For this reason and others, in recent years,
the 5-aminosalicylic acid-containing pro-drug balsalazide
has been the focus of attention. In a very recent metanal-
yses study Balsalazide was more effective than mesala-
mine in induction of remission, but balsalazide had no
benefit compared with mesalamine in preventing relapse
in the population selected. The number of patients with
any adverse events and withdrawals because of severe
adverse events was similar for mesalamine and balsalaz-
ide [35].
The pathophysiology of IBD is reflected by a distorted
balance of regulatory cytokines [27]. We have previously
reported the in vitro inhibition of IL1β, a pro-inflamma-
tory cytokine, in immune cells by PEO [19]. In colitis tis-Dey et al. BMC Chemical Biology 2010, 10:4
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sue, the expression of IL1β increases in immune-
challenged cells due to the activation of nuclear factor
kappaB (NFκB) [34]. Also, local high production of IL-1β
leads to tissue damage in IBD patients [1,36]. In the pres-
ent study we observed a significant PEO-mediated reduc-
tion of IL1β protein in the gut tissue (Fig 3).
The NFκB and STATs are two important families of
transcription factors that are activated in response to a
variety of stimuli to regulate multiple cellular processes
including immune response. The NFκB and STATs have
distinct as well as synergistic effects on gene induction
[37]. STAT proteins (7 reported in mammals) are dor-
mant cytoplasmic transcription factors that become acti-
vated after phosphorylation by Janus kinases or other
kinases in response to various stimuli including cytok-
ines, growth factors and LPS [37]. The activated protein
migrates into the nucleus and binds to specific promoter
e lemen ts t o regula t e gene e xpr ession [31]. ST A T regu-
lated genes include inducible nitric oxide synthase
(iNOS) [38], and CXCL10 [30] among others. The role of
NFκB in IBD [34] as well as effect of PEITC on NFκB
activity [16-18,20] are well studied. Excepting a very
recent report on STAT3 [26], the effect of PEITC on
STATs however has not been investigated.
An increase in STAT1 expression and activation in
human UC was observed by Schreiber et al., [27]. In addi-
tion, a number of studies have also reported an increased
expression of CXCL10 in the serum and mucosa of
patients with UC [29,39,40]. The CXCL10 is a STAT1
responsive, CXC chemokine that promotes the migration
of activated T cells. It is secreted by a variety of cell types,
including macrophages [29]. The gene array analysis in
the present study detected greater than three-fold sup-
pression of STAT1 and CXCL10 mRNA by 10 μM PEO in
LPS activated mouse macrophages (Table 5). Since it was
previously unknown that PEITC/PEO can attenuate the
expression of these genes (CXCL10 and STAT1), we fur-
ther confirmed a concentration-dependent suppression
of expression of these two genes by PEO (Fig 4, 5).
In macrophages we also observed a novel dose-depen-
dent decrease of activated STAT1 (pSTAT1) in the
n u c l e u s  b y  P E O / P E I T C  ( F i g  5 ) .  T h i s  i s  a n  i n t e r e s t i n g
observation given that macrophages are cells of mono-
cytic lineage, and phosphorylated (p) STAT1 was mainly
detected in monocytic cells and neutrophils in the
inflamed mucosa of ulcerative colitis patients [27]. The
inhibition of pSTAT1 by PEO is also consistent with our
current and previous findings that CXCL10 and iNOS
[19] mRNA are down regulated by PEO in activated mac-
rophages. Since STAT1 regulates iNOS [38] and CXCL10
[30,41], suppression of pSTAT1 by PEO likely contributes
to the downstream inhibition of iNOS and CXCL10.
Based on our current observations we hypothesize that
the decrease in nuclear pSTAT1 is primarily due to lower
levels cytoplasmic STAT1 protein (Fig 5) that serves as
the kinase substrate before translocation. We have initi-
ated a detailed investigation into the molecular mecha-
nism of suppression of STAT1 activation by PEO that will
be described elsewhere in the future.
Published reports suggest the important role of IL-6
signaling in the development of IBD [28]. IL6 signaling is
mediated by STAT3 that is also associated with colitis
disease development [28]. PEITC has been shown to sup-
press STAT3 activation [26] but its direct effect on IL6
expression has not been reported. The gene array data in
the current study show down-regulation of this proin-
flammatory cytokine by PEO in elicited macrophages
(Table 5). We confirmed this observation using a concen-
tration-dependent mRNA inhibition of IL6 by PEO (Fig
4).
In summary, orally administered PEO is pharmacologi-
cally active at remitting acute and chronic bowel inflam-
mation in experimental colitis in a mammalian model
system. The biological activity of PEO may be partly
mediated by the inhibition of pro-inflammatory cytok-
ines and chemokines produced by infiltrating immune
cells in the inflamed gut such as macrophages, thereby
attenuating signs of tissue damage. The gene expression
data further indicate that PEO affects an intricate net-
work of cellular targets of IBD including but not limited
to STAT1 mediated signaling. Taken together, the physio-
logical, histopathological and molecular findings of this
study suggest that PEO might provide promising new
therapeutic lead for the treatment of IBD.
Conclusions
Orally administered PEO is pharmacologically active at
remitting acute and chronic bowel inflammation in
experimental colitis in a mammalian system. The physio-
logical, histopathological and molecular findings of this
study suggest that PEO might provide promising new
therapeutic lead for the treatment of IBD.
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